Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 32
Encontrada(s) 1 página(s)

DAU Arxiu Digital de la Universitat Ramon Llull
Publication Artículo científico (JournalArticle)

Mediterranean diet and antihypertensive drug use: a randomized controlled trial

  • Ribó-Coll, Margarita
  • Lassale, Camille
  • Sacanella Meseguer, Emilio
  • Ros Rahola, Emilio
  • Toledo, Estefanía
  • Sorlí, José V.
  • Babio, Nancy
  • Lapetra, José
  • Gómez-Gracia, Enrique
  • Alonso Gómez, Ángel M.
  • Fiol, Miquel
  • Serra Majem, Lluís
  • Pintó Sala, Xavier
  • Castañer, Olga
  • Díez Espino, Javier
  • González, José I.
  • Becerra-Tomás, Nerea
  • Cofán Pujol, Montserrat
  • Díaz López, Andrés
  • Estruch Riba, Ramon
  • Hernáez, Álvaro
Objective: To examine in older individuals at high cardiovascular risk whether following a Mediterranean diet decreased the necessity of antihypertensive drugs and modulated their associated cardiovascular risk. Methods: In the PREvención con DIeta MEDiterránea study, we assessed whether volunteers randomly allocated to an intervention with a Mediterranean diet enriched with extra-virgin olive oil or nuts (relative to a low-fat control diet) disclosed differences in the risk of: initiating antihypertensive medication in nonusers at baseline (n = 2188); and escalating therapy in participants using one, two, or three drugs at baseline (n = 2361, n = 1579, and n = 554, respectively). We also assessed whether allocation to Mediterranean diet modified the association between antihypertensive drug use and incident cardiovascular events. Results: Participants allocated to Mediterranean diet interventions were associated with lower risk of initiating antihypertensive therapy [5-year incidence rates: 47.1% in the control diet, 43.0% in MedDiets; hazard ratio = 0.84, 95% CI (0.74--0.97), in a model adjusted for age, sex, and recruitment site]. Volunteers using two drugs at baseline in the Mediterranean diet intervention enriched with extra-virgin olive oil decreased their risk of therapy escalation [5-year incidence rates: 22.9% in the control diet, 20.1% in the MedDiet; hazard ratio = 0.77, 95% CI (0.60--0.99)]. Allocation to Mediterranean diet interventions attenuated the association between antihypertensive therapy at baseline and incidence of major adverse cardiovascular events (P interaction = 0.003). Conclusion: In an older population at high cardiovascular risk, following a Mediterranean diet reduced the risk of initiating or escalating antihypertensive medication and attenuated cardiovascular risk in antihypertensive drug users., info:eu-repo/semantics/acceptedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publication Artículo científico (JournalArticle)

Exceso de peso en España: situación actual, proyecciones para 2030 y sobrecoste directo estimado para el Sistema Nacional de Salud, Excess weight in Spain: current situation, projections for 2030, and estimated direct extra cost for the Spanish Health System

  • Hernáez, Álvaro
  • Zomeño, M. Dolores
  • Degano, Irene R.
  • Pérez Fernández, Sílvia
  • Goday, Alberto
  • Vila, Joan
  • Civeira, Fernando
  • Moure, Ricardo
  • Marrugat, Jaume
Introducción y objetivos El exceso de peso potencia algunas enfermedades crónicas y reduce la calidad de vida, y su prevalencia crece en todo el mundo. El objetivo es estimar la evolución del exceso de peso entre 1987 y 2014 en población española adulta, calcular los casos de exceso de peso y sus sobrecostes médicos directos en 2006 y 2016, y proyectar su tendencia a 2030. Métodos Se seleccionaron 47 artículos en una búsqueda bibliográfica sistemática para determinar la progresión de las prevalencias de sobrepeso, obesidad y obesidad mórbida y del índice de masa corporal promedio entre 1987 y 2014. Con estos datos, se estimó el número de casos en adultos españoles en 2006, 2016 y 2030 y sus sobrecostes directos. Resultados Entre 1987 y 2014, las prevalencias de sobrepeso, obesidad y obesidad mórbida aumentaron el 0,28%/año (p=0,004), el 0,50%/año (p<0,001) y el 0,030%/año (p=0,006) en los varones y el 0,10%/año (p=0,123), el 0,25%/año (p=0,078) y el 0,042%/año (p=0,251) en las mujeres. El índice de masa corporal aumentó 0,10 puntos/año en varones (p<0,001) y 0,26 en mujeres (significativamente solo entre 1987-2002, p <0,001). Se estimaron 23.500.000 casos de exceso de peso en 2016, cuyo sobrecoste médico directo supuso 1.950.000.000 euros/año. De mantenerse la tendencia, entre 2016 y 2030 aparecerán 3.100.000 nuevos casos de exceso de peso, y se alcanzará en 2030 un sobrecoste médico directo de unos 3.000.000.000 euros/año. Conclusiones El exceso de peso en los adultos en España aumenta desde que existen registros, y en 2016 supuso un sobrecoste directo del 2% del presupuesto sanitario. Con esta tendencia, en 2030 se habrá incrementado un 16% el número de casos y un 58% su sobrecoste sanitario directo., Introduction and objectives Excess weight promotes the development of several chronic diseases and decreases quality of life. Its prevalence is increasing globally. Our aim was to estimate the trend in excess weight between 1987 and 2014 in Spanish adults, calculate cases of excess weight and its direct extra costs in 2006 and 2016, and project its trend to 2030. Methods We selected 47 articles in a systematic literature search to determine the progression of the prevalence of overweight, nonmorbid obesity, and morbid obesity and average body mass index between 1987 and 2014. We projected the expected number of cases in 2006, 2016, and 2030 and the associated direct extra medical costs. Results Between 1987 and 2014, the prevalence of overweight, obesity, and morbid obesity increased by 0.28%/y (P=.004), 0.50%/y (P <.001) and 0.030%/y (P=.006) in men, and by 0.10%/y (P=.123), 0.25%/y (P=.078), and 0.042%/y (P=.251) in women. The mean body mass index increased by 0.10 kg/m2/y in men (P <.001) and 0.26 kg/m2/y in women (significantly only between 1987 and 2002, P <.001). We estimated 23 500 000 patients with excess weight in 2016, generating 1.95 billion €/y in direct extra medical costs. If the current trend continues, between 2016 and 2030, there will be 3 100 000 new cases of excess weight, leading to 3.0 billion €/y of direct extra medical costs in 2030. Conclusions Excess weight in Spanish adults has risen since the creation of population registries, generating direct extra medical costs that represent 2% of the 2016 health budget. If this trend continues, we expect 16% more cases in 2030 and 58% more direct extra medical costs., info:eu-repo/semantics/acceptedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publication Artículo científico (JournalArticle)

Mediterranean diet and physical activity decrease the initiation of cardiovascular drug use in high cardiovascular risk individuals: A cohort study

  • Ribó-Coll, Margarita
  • Castro-Barquero, Sara
  • Lassale, Camille
  • Sacanella Meseguer, Emilio
  • Ros Rahola, Emilio
  • Toledo, Estefanía
  • Sorlí, José V.
  • Díaz López, Andrés
  • Lapetra, José
  • Muñoz-Bravo, Carlos
  • Arós, Fernando
  • Fiol, Miquel
  • Serra Majem, Lluís
  • Pintó Sala, Xavier
  • Castañer, Olga
  • Fernandez-Lazaro, Cesar I.
  • Portolés, Olga
  • Babio, Nancy
  • Estruch Riba, Ramon
  • Hernáez, Álvaro
Our aim was to assess whether long-term adherence to a Mediterranean diet (MedDiet) and leisure-time physical activity (LTPA) were associated with a lower initiation of cardiovascular drug use. We studied the association between cumulative average of MedDiet adherence and LTPA and the risk of cardiovascular drug initiation in older adults at high cardiovascular risk (PREvención con DIeta MEDiterránea trial participants) non-medicated at baseline: glucose-lowering drugs (n = 4437), antihypertensives (n = 2145), statins (n = 3977), fibrates (n = 6391), antiplatelets (n = 5760), vitamin K antagonists (n = 6877), antianginal drugs (n = 6837), and cardiac glycosides (n = 6954). One-point increases in MedDiet adherence were linearly associated with a decreased initiation of glucose-lowering (HR: 0.76 [0.71–0.80]), antihypertensive (HR: 0.79 [0.75–0.82]), statin (HR: 0.82 [0.78–0.85]), fibrate (HR: 0.78 [0.68–0.89]), antiplatelet (HR: 0.79 [0.75–0.83]), vitamin K antagonist (HR: 0.83 [0.74; 0.93]), antianginal (HR: 0.84 [0.74–0.96]), and cardiac glycoside therapy (HR: 0.69 [0.56–0.84]). LTPA was non-linearly related to a delayed initiation of glucose-lowering, antihypertensive, statin, fibrate, antiplatelet, antianginal, and cardiac glycoside therapy (minimum risk: 180–360 metabolic equivalents of task-min/day). Both combined were synergistically associated with a decreased onset of glucose-lowering drugs (p-interaction = 0.04), antihypertensive drugs (p-interaction < 0.001), vitamin K antagonists (p-interaction = 0.04), and cardiac glycosides (p-interaction = 0.01). Summarizing, sustained adherence to a MedDiet and LTPA were associated with lower risk of initiating cardiovascular-related medications., info:eu-repo/semantics/publishedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publication Artículo científico (JournalArticle)

Modification of high-density lipoprotein functions by diet and other lifestyle changes: A systematic review of randomized controlled trials

  • Sanllorente Melenchon, Albert
  • Lassale, Camille
  • Soria Florido, María Trinidad
  • Castañer, Olga
  • Fitó Colomer, Montserrat
  • Hernáez, Álvaro
High-density lipoprotein (HDL) functional traits have emerged as relevant elements that may explain HDL antiatherogenic capacity better than HDL cholesterol levels. These properties have been improved in several lifestyle intervention trials. The aim of this systematic review is to summarize the results of such trials of the most commonly used dietary modifications (fatty acids, cholesterol, antioxidants, alcohol, and calorie restriction) and physical activity. Articles were screened from the Medline database until March 2021, and 118 randomized controlled trials were selected. Results from HDL functions and associated functional components were extracted, including cholesterol efflux capacity, cholesteryl ester transfer protein, lecithin-cholesterol acyltransferase, HDL antioxidant capacity, HDL oxidation status, paraoxonase-1 activity, HDL anti-inflammatory and endothelial protection capacity, HDL-associated phospholipase A2, HDL-associated serum amyloid A, and HDL-alpha-1-antitrypsin. In mainly short-term clinical trials, the consumption of monounsaturated and polyunsaturated fatty acids (particularly omega-3 in fish), and dietary antioxidants showed benefits to HDL functionality, especially in subjects with cardiovascular risk factors. In this regard, antioxidant-rich dietary patterns were able to improve HDL function in both healthy individuals and subjects at high cardiovascular risk. In addition, in randomized trial assays performed mainly in healthy individuals, reverse cholesterol transport with ethanol in moderate quantities enhanced HDL function. Nevertheless, the evidence summarized was of unclear quality and short-term nature and presented heterogeneity in lifestyle modifications, trial designs, and biochemical techniques for the assessment of HDL functions. Such findings should therefore be interpreted with caution. Large-scale, long-term, randomized, controlled trials in different populations and individuals with diverse pathologies are warranted., info:eu-repo/semantics/publishedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publication Artículo científico (JournalArticle)

Increased consumption of virgin olive oil, nuts, legumes, whole grains, and fish promotes HDL functions in humans

  • Hernáez, Álvaro
  • Sanllorente Melenchon, Albert
  • Castañer, Olga
  • Martínez-González, Miguel Ángel, 1957-
  • Ros Rahola, Emilio
  • Pintó Sala, Xavier
  • Estruch Riba, Ramon
  • Salas Salvadó, Jordi
  • Corella Piquer, Dolores
  • Alonso Gómez, Ángel M.
  • Serra Majem, Lluís
  • Fiol, Miquel
  • Lapetra, José
  • Gómez-Gracia, Enrique
  • de la Torre, Rafael
  • Lamuela Raventós, Rosa Ma.
  • Fitó Colomer, Montserrat
Scope To evaluate whether increases in the consumption of cardioprotective food groups (virgin olive oil, nuts, fruits/vegetables, legumes, whole grains, fish, and wine) are associated with improvements in high-density lipoprotein (HDL) functions in high cardiovascular risk subjects. Methods and Results The association between 1-year changes in food group consumption and HDL functionality traits in 296 high cardiovascular risk subjects is assessed. Increases in virgin olive oil (10 g d–1) and whole grain consumption (25 g d–1) are associated with increments in cholesterol efflux capacity (+0.7%, P = 0.026, and +0.6%, P = 0.017, respectively). Increases in nut (30 g d–1) and legume intake (25 g d–1) are linked to increments in paraoxonase-1 activity (+12.2%, P = 0.049, and +11.7%, P = 0.043, respectively). Legume intake increases are also related to decreases in cholesteryl ester transfer protein activity (–4.8%, P = 0.028). Fish consumption increments (25 g d–1) are associated with increases in paraoxonase-1 activity (+3.9%, P = 0.030) and declines in cholesteryl ester transfer protein activity (–1.6%, P = 0.021), HDL cholesterol concentrations (–1.1%, P = 0.039), and functions related to HDL levels (cholesterol efflux capacity, –1.1%, P = 0.010). Conclusion Increases in the consumption of virgin olive oil, nuts, legumes, whole grains, and fish (achievable through a regular diet) were associated with improvements in HDL functions in high cardiovascular risk subjects., info:eu-repo/semantics/acceptedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publication Artículo científico (JournalArticle)

Energy balance and risk of mortality in Spanish older adults

  • Lassale, Camille
  • Hernáez, Álvaro
  • Toledo, Estefanía
  • Castañer, Olga
  • Sorlí, José V.
  • Salas Salvadó, Jordi
  • Estruch Riba, Ramon
  • Ros Rahola, Emilio
  • Alonso Gómez, Ángel M.
  • Lapetra, José
  • Cueto, Raquel
  • Fiol, Miquel
  • Serra Majem, Lluís
  • Pintó Sala, Xavier
  • Gea, Alfredo
  • Corella Piquer, Dolores
  • Babio, Nancy
  • Fitó Colomer, Montserrat
  • Schröder, Helmut
Clinical data on the direct health effects of energy deficit or surplus beyond its impact on body weight are scarce. We aimed to assess the association with all-cause, cardiovascular and cancer mortality of (1) sustained energy deficit or surplus, calculated according to each individual’s en-ergy intake (EI) and theoretical energy expenditure (TEE), and (2) mid-term change in total EI in a prospective study. In 7119 participants in the PREDIMED Study (PREvención con DIeta MEDi-terránea) with a mean age of 67 years, energy intake was derived from a 137-item food frequency questionnaire. TEE was calculated as a function of age, sex, height, body weight and physical ac-tivity. The main exposure was the proportion of energy requirement covered by energy intake, cumulative throughout the follow-up. The secondary exposure was the change in energy intake from baseline. Cox proportional hazard models were used to estimate hazard ratios and 95% con-fidence intervals for all-cause, cardiovascular and cancer mortality. Over a median follow-up of 4.8 years, there were 239 deaths (excluding the first 2 years). An energy intake exceeding energy needs was associated with an increase in mortality risk (continuous HR10% over energy needs = 1.10; 95% CI 1.02, 1.18), driven by cardiovascular death (HR = 1.26; 95% CI 1.11, 1.43). However, consum-ing energy below estimated needs was not associated with a lower risk. Increments over time in energy intake were associated with greater all-cause mortality (HR10% increase = 1.09; 95% CI 1.02, 1.17). However, there was no evidence that a substantial negative change in energy intake would reduce mortality risk. To conclude, in an older Mediterranean cohort, energy surplus or increase over a 5-year period was associated with greater risk of mortality, particularly cardiovascular mortality. Energy deficit, or reduction in energy intake over time were not associated with mortal-ity risk., info:eu-repo/semantics/publishedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publication Artículo científico (JournalArticle)

Mediterranean diet and white blood cell count — A randomized controlled trial

  • Hernáez, Álvaro
  • Lassale, Camille
  • Castro-Barquero, Sara
  • Babio, Nancy
  • Ros Rahola, Emilio
  • Castañer, Olga
  • Tresserra-Rimbau, Anna
  • Pintó Sala, Xavier
  • Martínez-González, Miguel Ángel
  • Corella Piquer, Dolores
  • Salas Salvadó, Jordi
  • Alonso Gómez, Ángel M.
  • Lapetra, José
  • Fiol, Miquel
  • Gómez-Gracia, Enrique
  • Serra Majem, Lluís
  • Sacanella Meseguer, Emilio
  • García-Arellano, Ana
  • Sorlí, José V.
  • Díaz López, Andrés
  • Cofán Pujol, Montserrat
  • Estruch Riba, Ramon
We aimed to assess the effects of the antioxidant-rich Mediterranean diet (MedDiet) on white blood cell count. Our study population included participants in the PREvención con DIeta MEDiterránea study (average age 67 years old, 58% women, high cardiovascular risk). We assessed whether a MedDiet intervention enriched in extra-virgin olive oil or nuts, versus a low-fat control diet, modified the incidence of leukocytosis (>11 × 109 leukocytes/L), mild leukopenia (<4.5 × 109 leukocytes/L), or severe leukopenia (<3.5 × 109 leukocytes/L) in individuals without the condition at baseline (n = 3190, n = 2925, and n = 3190, respectively). We also examined whether MedDiet modified the association between leukocyte count alterations and all-cause mortality. Both MedDiet interventions were associated with a lower risk of developing leukopenia (incidence rates: 5.06% in control diet, 3.29% in MedDiet groups combined; hazard ratio [95% confidence interval]: 0.54 [0.36–0.80]) and severe leukopenia (incidence rates: 1.26% in control diet, 0.46% in MedDiet groups combined; hazard ratio: 0.25 [0.10–0.60]). High cumulative adherence to a MedDiet was linked to lower risk of leukocytosis (incidence rates: 2.08% in quartile 1, 0.65% in quartile 4; HRQ4-Q1: 0.29 [0.085–0.99]) and attenuated the association between leukopenia and all-cause mortality (P-interaction = 0.032). In brief, MedDiet decreased the incidence of white blood cell count-related alterations in high cardiovascular risk individuals., info:eu-repo/semantics/publishedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publication Artículo científico (JournalArticle)

Mediterranean diet decreases the initiation of use of vitamin K epoxide reductase inhibitors and their associated cardiovascular risk: a randomized controlled trial

  • Castro-Barquero, Sara
  • Ribó-Coll, Margarita
  • Lassale, Camille
  • Tresserra-Rimbau, Anna
  • Castañer, Olga
  • Pintó Sala, Xavier
  • Martínez-González, Miguel Ángel, 1957-
  • Sorlí, José V.
  • Salas Salvadó, Jordi
  • Lapetra, José
  • Gómez-Gracia, Enrique
  • Alonso Gómez, Ángel M.
  • Fiol Sala, Miguel
  • Serra Majem, Lluís
  • Sacanella Meseguer, Emilio
  • Basterra-Gortari, Francisco Javier
  • Portolés, Olga
  • Babio, Nancy
  • Cofán Pujol, Montserrat
  • Ros Rahola, Emilio
  • Estruch Riba, Ramon
  • Hernáez, Álvaro
Our aim is to assess whether following a Mediterranean Diet (MedDiet) decreases the risk of initiating antithrombotic therapies and the cardiovascular risk associated with its use in older individuals at high cardiovascular risk. We evaluate whether participants of the PREvención con DIeta MEDiterránea (PREDIMED) study allocated to a MedDiet enriched in extra-virgin olive oil or nuts (versus a low-fat control intervention) disclose differences in the risk of initiation of: (1) vitamin K epoxide reductase inhibitors (acenocumarol/warfarin; n = 6772); (2) acetylsalicylic acid as antiplatelet agent (n = 5662); and (3) other antiplatelet drugs (cilostazol/clopidogrel/dipyridamole/ditazol/ticlopidine/triflusal; n = 6768). We also assess whether MedDiet modifies the association between the antithrombotic drug baseline use and incident cardiovascular events. The MedDiet intervention enriched with extra-virgin olive oil decreased the risk of initiating the use of vitamin K epoxide reductase inhibitors relative to control diet (HR: 0.68 [0.46–0.998]). Their use was also more strongly associated with an increased risk of cardiovascular disease in participants not allocated to MedDiet interventions (HRcontrol diet: 4.22 [1.92–9.30], HRMedDiets: 1.71 [0.83–3.52], p-interaction = 0.052). In conclusion, in an older population at high cardiovascular risk, following a MedDiet decreases the initiation of antithrombotic therapies and the risk of suffering major cardiovascular events among users of vitamin K epoxide reductase inhibitors.
DAU Arxiu Digital de la Universitat Ramon Llull
Publication Artículo científico (JournalArticle)

Mediterranean diet maintained platelet count within a healthy range and decreased thrombocytopenia-related mortality risk: a randomized controlled trial

  • Hernáez, Álvaro
  • Lassale, Camille
  • Castro-Barquero, Sara
  • Ros Rahola, Emilio
  • Tresserra-Rimbau, Anna
  • Castañer, Olga
  • Pintó Sala, Xavier
  • Vázquez Ruiz, Zenaida
  • Sorlí, José V.
  • Salas Salvadó, Jordi
  • Lapetra, José
  • Gómez-Gracia, Enrique
  • Alonso Gómez, Ángel M.
  • Fiol, Miquel
  • Serra Majem, Lluís
  • Sacanella Meseguer, Emilio
  • Razquin, Cristina
  • Corella Piquer, Dolores
  • Guasch-Ferré, Marta
  • Cofán Pujol, Montserrat
  • Estruch Riba, Ramon
There is little information on the dietary modulation of thrombosis-related risk factors such as platelet count. We aimed to assess the effects of Mediterranean diet (MedDiet) on platelet count and related outcomes in an older population at high cardiovascular risk. In participants of the PREDIMED (PREvención con DIeta MEDiterránea) study, we assessed whether an intervention with a MedDiet enriched with extra-virgin olive oil or nuts, relative to a low-fat control diet, modulated platelet count (n = 4189), the risk of developing thrombocytosis and thrombocytopenia (n = 3086), and the association between these alterations and all-cause mortality (median follow-up time: 3.0 years). Although platelet count increased over time (+0.98·109 units/L·year [95% confidence interval: 0.12; 1.84]), MedDiet interventions moderated this increase, particularly in individuals with near-high baseline count (both MedDiets combined: −3.20·109 units/L·year [−5.81; −0.59]). Thrombocytopenia incidence was lower in the MedDiet interventions (incidence rates: 2.23% in control diet, 0.91% in MedDiets combined; hazard ratio: 0.44 [0.23; 0.83]). Finally, thrombocytopenia was associated with a higher risk of all-cause mortality (hazard ratio: 4.71 [2.69; 8.24]), but this relationship was attenuated in those allocated to MedDiet (p-interaction = 0.018). In brief, MedDiet maintained platelet counts within a healthy range and attenuated platelet-related mortality in older adults at high cardiovascular risk.
DAU Arxiu Digital de la Universitat Ramon Llull
Publication Artículo científico (JournalArticle)

High-density lipoprotein characteristics and coronary artery disease: a Mendelian randomization study

  • Prats Uribe, Albert
  • Sayols Baixeras, Sergi
  • Fernández Sanlés, Alba
  • Subirana, Isaac
  • Carreras-Torres, Robert
  • Vilahur, Gemma
  • Civeira, Fernando
  • Marrugat, Jaume
  • Fitó Colomer, Montserrat
  • Hernáez, Álvaro
  • Elosua Llanos, Roberto
Background To assess whether genetically determined quantitative and qualitative HDL characteristics were independently associated with coronary artery disease (CAD). Methods We designed a two-sample multivariate Mendelian randomization study with available genome-wide association summary data. We identified genetic variants associated with HDL cholesterol and apolipoprotein A-I levels, HDL size, particle levels, and lipid content to define our genetic instrumental variables in one sample (Kettunen et al. study, n = 24,925) and analyzed their association with CAD risk in a different study (CARDIoGRAMplusC4D, n = 184,305). We validated these results by defining our genetic variables in another database (METSIM, n = 8372) and studied their relationship with CAD in the CARDIoGRAMplusC4D dataset. To estimate the effect size of the associations of interest adjusted for other lipoprotein traits and minimize potential pleiotropy, we used the Multi-trait-based Conditional & Joint analysis. Results Genetically determined HDL cholesterol and apolipoprotein A-I levels were not associated with CAD. HDL mean diameter (β = 0.27 [95%CI = 0.19; 0.35]), cholesterol levels in very large HDLs (β = 0.29 [95%CI = 0.17; 0.40]), and triglyceride content in very large HDLs (β = 0.14 [95%CI = 0.040; 0.25]) were directly associated with CAD risk, whereas the cholesterol content in medium-sized HDLs (β = −0.076 [95%CI = -0.10; −0.052]) was inversely related to this risk. These results were validated in the METSIM-CARDIoGRAMplusC4D data. Conclusions Some qualitative HDL characteristics (related to size, particle distribution, and cholesterol and triglyceride content) are related to CAD risk while HDL cholesterol levels are not., info:eu-repo/semantics/acceptedVersion
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

High-density lipoprotein characteristics and coronary artery disease: a Mendelian randomization study

  • Prats-Uribe, A.
  • Sayols-Baixeras, S.
  • Fernández-Sanlés, A.
  • Subirana, I.
  • Carreras-Torres, R.
  • Vilahur, G.
  • Civeira, F.
  • Marrugat, J.
  • Fitó, M.
  • Hernáez, Á.
  • Elosua, R.
Background: To assess whether genetically determined quantitative and qualitative HDL characteristics were independently associated with coronary artery disease (CAD). Methods: We designed a two-sample multivariate Mendelian randomization study with available genome-wide association summary data. We identified genetic variants associated with HDL cholesterol and apolipoprotein A-I levels, HDL size, particle levels, and lipid content to define our genetic instrumental variables in one sample (Kettunen et al. study, n = 24, 925) and analyzed their association with CAD risk in a different study (CARDIoGRAMplusC4D, n = 184, 305). We validated these results by defining our genetic variables in another database (METSIM, n = 8372) and studied their relationship with CAD in the CARDIoGRAMplusC4D dataset. To estimate the effect size of the associations of interest adjusted for other lipoprotein traits and minimize potential pleiotropy, we used the Multi-trait-based Conditional & Joint analysis. Results: Genetically determined HDL cholesterol and apolipoprotein A-I levels were not associated with CAD. HDL mean diameter (ß = 0.27 [95%CI = 0.19; 0.35]), cholesterol levels in very large HDLs (ß = 0.29 [95%CI = 0.17; 0.40]), and triglyceride content in very large HDLs (ß = 0.14 [95%CI = 0.040; 0.25]) were directly associated with CAD risk, whereas the cholesterol content in medium-sized HDLs (ß = -0.076 [95%CI = -0.10; -0.052]) was inversely related to this risk. These results were validated in the METSIM-CARDIoGRAMplusC4D data. Conclusions: Some qualitative HDL characteristics (related to size, particle distribution, and cholesterol and triglyceride content) are related to CAD risk while HDL cholesterol levels are not.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Mediterranean diet and white blood cell count — A randomized controlled trial

  • Hernáez, Álvaro
  • Lassale, Camille
  • Castro-Barquero, Sara
  • Babio, Nancy
  • Ros Rahola, Emilio
  • Castañer, Olga
  • Tresserra-Rimbau, Anna
  • Pintó Sala, Xavier
  • Martínez-González, Miguel Ángel
  • Corella Piquer, Dolores
  • Salas Salvadó, Jordi
  • Alonso Gómez, Ángel M.
  • Lapetra, José
  • Fiol, Miquel
  • Gómez-Gracia, Enrique
  • Serra Majem, Lluís
  • Sacanella Meseguer, Emilio
  • García-Arellano, Ana
  • Sorlí, José V.
  • Díaz López, Andrés
  • Cofán Pujol, Montserrat
  • Estruch Riba, Ramon
We aimed to assess the effects of the antioxidant-rich Mediterranean diet (MedDiet) on white blood cell count. Our study population included participants in the PREvención con DIeta MEDiterránea study (average age 67 years old, 58% women, high cardiovascular risk). We assessed whether a MedDiet intervention enriched in extra-virgin olive oil or nuts, versus a low-fat control diet, modified the incidence of leukocytosis (>11 × 109 leukocytes/L), mild leukopenia (<4.5 × 109 leukocytes/L), or severe leukopenia (<3.5 × 109 leukocytes/L) in individuals without the condition at baseline (n = 3190, n = 2925, and n = 3190, respectively). We also examined whether MedDiet modified the association between leukocyte count alterations and all-cause mortality. Both MedDiet interventions were associated with a lower risk of developing leukopenia (incidence rates: 5.06% in control diet, 3.29% in MedDiet groups combined; hazard ratio [95% confidence interval]: 0.54 [0.36–0.80]) and severe leukopenia (incidence rates: 1.26% in control diet, 0.46% in MedDiet groups combined; hazard ratio: 0.25 [0.10–0.60]). High cumulative adherence to a MedDiet was linked to lower risk of leukocytosis (incidence rates: 2.08% in quartile 1, 0.65% in quartile 4; HRQ4-Q1: 0.29 [0.085–0.99]) and attenuated the association between leukopenia and all-cause mortality (P-interaction = 0.032). In brief, MedDiet decreased the incidence of white blood cell count-related alterations in high cardiovascular risk individuals., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Modification of high-density lipoprotein functions by diet and other lifestyle changes: A systematic review of randomized controlled trials

  • Sanllorente Melenchon, Albert
  • Lassale, Camille
  • Soria Florido, María Trinidad
  • Castañer, Olga
  • Fitó Colomer, Montserrat
  • Hernáez, Álvaro
High-density lipoprotein (HDL) functional traits have emerged as relevant elements that may explain HDL antiatherogenic capacity better than HDL cholesterol levels. These properties have been improved in several lifestyle intervention trials. The aim of this systematic review is to summarize the results of such trials of the most commonly used dietary modifications (fatty acids, cholesterol, antioxidants, alcohol, and calorie restriction) and physical activity. Articles were screened from the Medline database until March 2021, and 118 randomized controlled trials were selected. Results from HDL functions and associated functional components were extracted, including cholesterol efflux capacity, cholesteryl ester transfer protein, lecithin-cholesterol acyltransferase, HDL antioxidant capacity, HDL oxidation status, paraoxonase-1 activity, HDL anti-inflammatory and endothelial protection capacity, HDL-associated phospholipase A2, HDL-associated serum amyloid A, and HDL-alpha-1-antitrypsin. In mainly short-term clinical trials, the consumption of monounsaturated and polyunsaturated fatty acids (particularly omega-3 in fish), and dietary antioxidants showed benefits to HDL functionality, especially in subjects with cardiovascular risk factors. In this regard, antioxidant-rich dietary patterns were able to improve HDL function in both healthy individuals and subjects at high cardiovascular risk. In addition, in randomized trial assays performed mainly in healthy individuals, reverse cholesterol transport with ethanol in moderate quantities enhanced HDL function. Nevertheless, the evidence summarized was of unclear quality and short-term nature and presented heterogeneity in lifestyle modifications, trial designs, and biochemical techniques for the assessment of HDL functions. Such findings should therefore be interpreted with caution. Large-scale, long-term, randomized, controlled trials in different populations and individuals with diverse pathologies are warranted., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Mediterranean diet and physical activity decrease the initiation of cardiovascular drug use in high cardiovascular risk individuals: A cohort study

  • Ribó-Coll, Margarita
  • Castro-Barquero, Sara
  • Lassale, Camille
  • Sacanella Meseguer, Emilio
  • Ros Rahola, Emilio
  • Toledo, Estefanía
  • Sorlí, José V.
  • Díaz López, Andrés
  • Lapetra, José
  • Muñoz-Bravo, Carlos
  • Arós, Fernando
  • Fiol, Miquel
  • Serra Majem, Lluís
  • Pintó Sala, Xavier
  • Castañer, Olga
  • Fernandez-Lazaro, Cesar I.
  • Portolés, Olga
  • Babio, Nancy
  • Estruch Riba, Ramon
  • Hernáez, Álvaro
Our aim was to assess whether long-term adherence to a Mediterranean diet (MedDiet) and leisure-time physical activity (LTPA) were associated with a lower initiation of cardiovascular drug use. We studied the association between cumulative average of MedDiet adherence and LTPA and the risk of cardiovascular drug initiation in older adults at high cardiovascular risk (PREvención con DIeta MEDiterránea trial participants) non-medicated at baseline: glucose-lowering drugs (n = 4437), antihypertensives (n = 2145), statins (n = 3977), fibrates (n = 6391), antiplatelets (n = 5760), vitamin K antagonists (n = 6877), antianginal drugs (n = 6837), and cardiac glycosides (n = 6954). One-point increases in MedDiet adherence were linearly associated with a decreased initiation of glucose-lowering (HR: 0.76 [0.71–0.80]), antihypertensive (HR: 0.79 [0.75–0.82]), statin (HR: 0.82 [0.78–0.85]), fibrate (HR: 0.78 [0.68–0.89]), antiplatelet (HR: 0.79 [0.75–0.83]), vitamin K antagonist (HR: 0.83 [0.74; 0.93]), antianginal (HR: 0.84 [0.74–0.96]), and cardiac glycoside therapy (HR: 0.69 [0.56–0.84]). LTPA was non-linearly related to a delayed initiation of glucose-lowering, antihypertensive, statin, fibrate, antiplatelet, antianginal, and cardiac glycoside therapy (minimum risk: 180–360 metabolic equivalents of task-min/day). Both combined were synergistically associated with a decreased onset of glucose-lowering drugs (p-interaction = 0.04), antihypertensive drugs (p-interaction < 0.001), vitamin K antagonists (p-interaction = 0.04), and cardiac glycosides (p-interaction = 0.01). Summarizing, sustained adherence to a MedDiet and LTPA were associated with lower risk of initiating cardiovascular-related medications., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Energy balance and risk of mortality in Spanish older adults

  • Lassale, Camille
  • Hernáez, Álvaro
  • Toledo, Estefanía
  • Castañer, Olga
  • Sorlí, José V.
  • Salas Salvadó, Jordi
  • Estruch Riba, Ramon
  • Ros Rahola, Emilio
  • Alonso Gómez, Ángel M.
  • Lapetra, José
  • Cueto, Raquel
  • Fiol, Miquel
  • Serra Majem, Lluís
  • Pintó Sala, Xavier
  • Gea, Alfredo
  • Corella Piquer, Dolores
  • Babio, Nancy
  • Fitó Colomer, Montserrat
  • Schröder, Helmut
Clinical data on the direct health effects of energy deficit or surplus beyond its impact on body weight are scarce. We aimed to assess the association with all-cause, cardiovascular and cancer mortality of (1) sustained energy deficit or surplus, calculated according to each individual’s en-ergy intake (EI) and theoretical energy expenditure (TEE), and (2) mid-term change in total EI in a prospective study. In 7119 participants in the PREDIMED Study (PREvención con DIeta MEDi-terránea) with a mean age of 67 years, energy intake was derived from a 137-item food frequency questionnaire. TEE was calculated as a function of age, sex, height, body weight and physical ac-tivity. The main exposure was the proportion of energy requirement covered by energy intake, cumulative throughout the follow-up. The secondary exposure was the change in energy intake from baseline. Cox proportional hazard models were used to estimate hazard ratios and 95% con-fidence intervals for all-cause, cardiovascular and cancer mortality. Over a median follow-up of 4.8 years, there were 239 deaths (excluding the first 2 years). An energy intake exceeding energy needs was associated with an increase in mortality risk (continuous HR10% over energy needs = 1.10; 95% CI 1.02, 1.18), driven by cardiovascular death (HR = 1.26; 95% CI 1.11, 1.43). However, consum-ing energy below estimated needs was not associated with a lower risk. Increments over time in energy intake were associated with greater all-cause mortality (HR10% increase = 1.09; 95% CI 1.02, 1.17). However, there was no evidence that a substantial negative change in energy intake would reduce mortality risk. To conclude, in an older Mediterranean cohort, energy surplus or increase over a 5-year period was associated with greater risk of mortality, particularly cardiovascular mortality. Energy deficit, or reduction in energy intake over time were not associated with mortal-ity risk., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Exceso de peso en España: situación actual, proyecciones para 2030 y sobrecoste directo estimado para el Sistema Nacional de Salud, Excess weight in Spain: current situation, projections for 2030, and estimated direct extra cost for the Spanish Health System

  • Hernáez, Álvaro
  • Zomeño, M. Dolores
  • Degano, Irene R.
  • Pérez Fernández, Sílvia
  • Goday, Alberto
  • Vila, Joan
  • Civeira, Fernando
  • Moure, Ricardo
  • Marrugat, Jaume
Introducción y objetivos El exceso de peso potencia algunas enfermedades crónicas y reduce la calidad de vida, y su prevalencia crece en todo el mundo. El objetivo es estimar la evolución del exceso de peso entre 1987 y 2014 en población española adulta, calcular los casos de exceso de peso y sus sobrecostes médicos directos en 2006 y 2016, y proyectar su tendencia a 2030. Métodos Se seleccionaron 47 artículos en una búsqueda bibliográfica sistemática para determinar la progresión de las prevalencias de sobrepeso, obesidad y obesidad mórbida y del índice de masa corporal promedio entre 1987 y 2014. Con estos datos, se estimó el número de casos en adultos españoles en 2006, 2016 y 2030 y sus sobrecostes directos. Resultados Entre 1987 y 2014, las prevalencias de sobrepeso, obesidad y obesidad mórbida aumentaron el 0,28%/año (p=0,004), el 0,50%/año (p<0,001) y el 0,030%/año (p=0,006) en los varones y el 0,10%/año (p=0,123), el 0,25%/año (p=0,078) y el 0,042%/año (p=0,251) en las mujeres. El índice de masa corporal aumentó 0,10 puntos/año en varones (p<0,001) y 0,26 en mujeres (significativamente solo entre 1987-2002, p <0,001). Se estimaron 23.500.000 casos de exceso de peso en 2016, cuyo sobrecoste médico directo supuso 1.950.000.000 euros/año. De mantenerse la tendencia, entre 2016 y 2030 aparecerán 3.100.000 nuevos casos de exceso de peso, y se alcanzará en 2030 un sobrecoste médico directo de unos 3.000.000.000 euros/año. Conclusiones El exceso de peso en los adultos en España aumenta desde que existen registros, y en 2016 supuso un sobrecoste directo del 2% del presupuesto sanitario. Con esta tendencia, en 2030 se habrá incrementado un 16% el número de casos y un 58% su sobrecoste sanitario directo., Introduction and objectives Excess weight promotes the development of several chronic diseases and decreases quality of life. Its prevalence is increasing globally. Our aim was to estimate the trend in excess weight between 1987 and 2014 in Spanish adults, calculate cases of excess weight and its direct extra costs in 2006 and 2016, and project its trend to 2030. Methods We selected 47 articles in a systematic literature search to determine the progression of the prevalence of overweight, nonmorbid obesity, and morbid obesity and average body mass index between 1987 and 2014. We projected the expected number of cases in 2006, 2016, and 2030 and the associated direct extra medical costs. Results Between 1987 and 2014, the prevalence of overweight, obesity, and morbid obesity increased by 0.28%/y (P=.004), 0.50%/y (P <.001) and 0.030%/y (P=.006) in men, and by 0.10%/y (P=.123), 0.25%/y (P=.078), and 0.042%/y (P=.251) in women. The mean body mass index increased by 0.10 kg/m2/y in men (P <.001) and 0.26 kg/m2/y in women (significantly only between 1987 and 2002, P <.001). We estimated 23 500 000 patients with excess weight in 2016, generating 1.95 billion €/y in direct extra medical costs. If the current trend continues, between 2016 and 2030, there will be 3 100 000 new cases of excess weight, leading to 3.0 billion €/y of direct extra medical costs in 2030. Conclusions Excess weight in Spanish adults has risen since the creation of population registries, generating direct extra medical costs that represent 2% of the 2016 health budget. If this trend continues, we expect 16% more cases in 2030 and 58% more direct extra medical costs., info:eu-repo/semantics/acceptedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Mediterranean diet maintained platelet count within a healthy range and decreased thrombocytopenia-related mortality risk: a randomized controlled trial

  • Hernáez, Álvaro
  • Lassale, Camille
  • Castro-Barquero, Sara
  • Ros Rahola, Emilio
  • Tresserra-Rimbau, Anna
  • Castañer, Olga
  • Pintó Sala, Xavier
  • Vázquez Ruiz, Zenaida
  • Sorlí, José V.
  • Salas Salvadó, Jordi
  • Lapetra, José
  • Gómez-Gracia, Enrique
  • Alonso Gómez, Ángel M.
  • Fiol, Miquel
  • Serra Majem, Lluís
  • Sacanella Meseguer, Emilio
  • Razquin, Cristina
  • Corella Piquer, Dolores
  • Guasch-Ferré, Marta
  • Cofán Pujol, Montserrat
  • Estruch Riba, Ramon
There is little information on the dietary modulation of thrombosis-related risk factors such as platelet count. We aimed to assess the effects of Mediterranean diet (MedDiet) on platelet count and related outcomes in an older population at high cardiovascular risk. In participants of the PREDIMED (PREvención con DIeta MEDiterránea) study, we assessed whether an intervention with a MedDiet enriched with extra-virgin olive oil or nuts, relative to a low-fat control diet, modulated platelet count (n = 4189), the risk of developing thrombocytosis and thrombocytopenia (n = 3086), and the association between these alterations and all-cause mortality (median follow-up time: 3.0 years). Although platelet count increased over time (+0.98·109 units/L·year [95% confidence interval: 0.12; 1.84]), MedDiet interventions moderated this increase, particularly in individuals with near-high baseline count (both MedDiets combined: −3.20·109 units/L·year [−5.81; −0.59]). Thrombocytopenia incidence was lower in the MedDiet interventions (incidence rates: 2.23% in control diet, 0.91% in MedDiets combined; hazard ratio: 0.44 [0.23; 0.83]). Finally, thrombocytopenia was associated with a higher risk of all-cause mortality (hazard ratio: 4.71 [2.69; 8.24]), but this relationship was attenuated in those allocated to MedDiet (p-interaction = 0.018). In brief, MedDiet maintained platelet counts within a healthy range and attenuated platelet-related mortality in older adults at high cardiovascular risk.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Mediterranean diet decreases the initiation of use of vitamin K epoxide reductase inhibitors and their associated cardiovascular risk: a randomized controlled trial

  • Castro-Barquero, Sara
  • Ribó-Coll, Margarita
  • Lassale, Camille
  • Tresserra-Rimbau, Anna
  • Castañer, Olga
  • Pintó Sala, Xavier
  • Martínez-González, Miguel Ángel, 1957-
  • Sorlí, José V.
  • Salas Salvadó, Jordi
  • Lapetra, José
  • Gómez-Gracia, Enrique
  • Alonso Gómez, Ángel M.
  • Fiol Sala, Miguel
  • Serra Majem, Lluís
  • Sacanella Meseguer, Emilio
  • Basterra-Gortari, Francisco Javier
  • Portolés, Olga
  • Babio, Nancy
  • Cofán Pujol, Montserrat
  • Ros Rahola, Emilio
  • Estruch Riba, Ramon
  • Hernáez, Álvaro
Our aim is to assess whether following a Mediterranean Diet (MedDiet) decreases the risk of initiating antithrombotic therapies and the cardiovascular risk associated with its use in older individuals at high cardiovascular risk. We evaluate whether participants of the PREvención con DIeta MEDiterránea (PREDIMED) study allocated to a MedDiet enriched in extra-virgin olive oil or nuts (versus a low-fat control intervention) disclose differences in the risk of initiation of: (1) vitamin K epoxide reductase inhibitors (acenocumarol/warfarin; n = 6772); (2) acetylsalicylic acid as antiplatelet agent (n = 5662); and (3) other antiplatelet drugs (cilostazol/clopidogrel/dipyridamole/ditazol/ticlopidine/triflusal; n = 6768). We also assess whether MedDiet modifies the association between the antithrombotic drug baseline use and incident cardiovascular events. The MedDiet intervention enriched with extra-virgin olive oil decreased the risk of initiating the use of vitamin K epoxide reductase inhibitors relative to control diet (HR: 0.68 [0.46–0.998]). Their use was also more strongly associated with an increased risk of cardiovascular disease in participants not allocated to MedDiet interventions (HRcontrol diet: 4.22 [1.92–9.30], HRMedDiets: 1.71 [0.83–3.52], p-interaction = 0.052). In conclusion, in an older population at high cardiovascular risk, following a MedDiet decreases the initiation of antithrombotic therapies and the risk of suffering major cardiovascular events among users of vitamin K epoxide reductase inhibitors.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Mediterranean diet and antihypertensive drug use: a randomized controlled trial

  • Ribó-Coll, Margarita
  • Lassale, Camille
  • Sacanella Meseguer, Emilio
  • Ros Rahola, Emilio
  • Toledo, Estefanía
  • Sorlí, José V.
  • Babio, Nancy
  • Lapetra, José
  • Gómez-Gracia, Enrique
  • Alonso Gómez, Ángel M.
  • Fiol, Miquel
  • Serra Majem, Lluís
  • Pintó Sala, Xavier
  • Castañer, Olga
  • Díez Espino, Javier
  • González, José I.
  • Becerra-Tomás, Nerea
  • Cofán Pujol, Montserrat
  • Díaz López, Andrés
  • Estruch Riba, Ramon
  • Hernáez, Álvaro
Objective: To examine in older individuals at high cardiovascular risk whether following a Mediterranean diet decreased the necessity of antihypertensive drugs and modulated their associated cardiovascular risk. Methods: In the PREvención con DIeta MEDiterránea study, we assessed whether volunteers randomly allocated to an intervention with a Mediterranean diet enriched with extra-virgin olive oil or nuts (relative to a low-fat control diet) disclosed differences in the risk of: initiating antihypertensive medication in nonusers at baseline (n = 2188); and escalating therapy in participants using one, two, or three drugs at baseline (n = 2361, n = 1579, and n = 554, respectively). We also assessed whether allocation to Mediterranean diet modified the association between antihypertensive drug use and incident cardiovascular events. Results: Participants allocated to Mediterranean diet interventions were associated with lower risk of initiating antihypertensive therapy [5-year incidence rates: 47.1% in the control diet, 43.0% in MedDiets; hazard ratio = 0.84, 95% CI (0.74--0.97), in a model adjusted for age, sex, and recruitment site]. Volunteers using two drugs at baseline in the Mediterranean diet intervention enriched with extra-virgin olive oil decreased their risk of therapy escalation [5-year incidence rates: 22.9% in the control diet, 20.1% in the MedDiet; hazard ratio = 0.77, 95% CI (0.60--0.99)]. Allocation to Mediterranean diet interventions attenuated the association between antihypertensive therapy at baseline and incidence of major adverse cardiovascular events (P interaction = 0.003). Conclusion: In an older population at high cardiovascular risk, following a Mediterranean diet reduced the risk of initiating or escalating antihypertensive medication and attenuated cardiovascular risk in antihypertensive drug users., info:eu-repo/semantics/acceptedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

High-density lipoprotein characteristics and coronary artery disease: a Mendelian randomization study

  • Prats Uribe, Albert
  • Sayols Baixeras, Sergi
  • Fernández Sanlés, Alba
  • Subirana, Isaac
  • Carreras-Torres, Robert
  • Vilahur, Gemma
  • Civeira, Fernando
  • Marrugat, Jaume
  • Fitó Colomer, Montserrat
  • Hernáez, Álvaro
  • Elosua Llanos, Roberto
Background To assess whether genetically determined quantitative and qualitative HDL characteristics were independently associated with coronary artery disease (CAD). Methods We designed a two-sample multivariate Mendelian randomization study with available genome-wide association summary data. We identified genetic variants associated with HDL cholesterol and apolipoprotein A-I levels, HDL size, particle levels, and lipid content to define our genetic instrumental variables in one sample (Kettunen et al. study, n = 24,925) and analyzed their association with CAD risk in a different study (CARDIoGRAMplusC4D, n = 184,305). We validated these results by defining our genetic variables in another database (METSIM, n = 8372) and studied their relationship with CAD in the CARDIoGRAMplusC4D dataset. To estimate the effect size of the associations of interest adjusted for other lipoprotein traits and minimize potential pleiotropy, we used the Multi-trait-based Conditional & Joint analysis. Results Genetically determined HDL cholesterol and apolipoprotein A-I levels were not associated with CAD. HDL mean diameter (β = 0.27 [95%CI = 0.19; 0.35]), cholesterol levels in very large HDLs (β = 0.29 [95%CI = 0.17; 0.40]), and triglyceride content in very large HDLs (β = 0.14 [95%CI = 0.040; 0.25]) were directly associated with CAD risk, whereas the cholesterol content in medium-sized HDLs (β = −0.076 [95%CI = -0.10; −0.052]) was inversely related to this risk. These results were validated in the METSIM-CARDIoGRAMplusC4D data. Conclusions Some qualitative HDL characteristics (related to size, particle distribution, and cholesterol and triglyceride content) are related to CAD risk while HDL cholesterol levels are not., info:eu-repo/semantics/acceptedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Increased consumption of virgin olive oil, nuts, legumes, whole grains, and fish promotes HDL functions in humans

  • Hernáez, Álvaro
  • Sanllorente Melenchon, Albert
  • Castañer, Olga
  • Martínez-González, Miguel Ángel, 1957-
  • Ros Rahola, Emilio
  • Pintó Sala, Xavier
  • Estruch Riba, Ramon
  • Salas Salvadó, Jordi
  • Corella Piquer, Dolores
  • Alonso Gómez, Ángel M.
  • Serra Majem, Lluís
  • Fiol, Miquel
  • Lapetra, José
  • Gómez-Gracia, Enrique
  • de la Torre, Rafael
  • Lamuela Raventós, Rosa Ma.
  • Fitó Colomer, Montserrat
Scope To evaluate whether increases in the consumption of cardioprotective food groups (virgin olive oil, nuts, fruits/vegetables, legumes, whole grains, fish, and wine) are associated with improvements in high-density lipoprotein (HDL) functions in high cardiovascular risk subjects. Methods and Results The association between 1-year changes in food group consumption and HDL functionality traits in 296 high cardiovascular risk subjects is assessed. Increases in virgin olive oil (10 g d–1) and whole grain consumption (25 g d–1) are associated with increments in cholesterol efflux capacity (+0.7%, P = 0.026, and +0.6%, P = 0.017, respectively). Increases in nut (30 g d–1) and legume intake (25 g d–1) are linked to increments in paraoxonase-1 activity (+12.2%, P = 0.049, and +11.7%, P = 0.043, respectively). Legume intake increases are also related to decreases in cholesteryl ester transfer protein activity (–4.8%, P = 0.028). Fish consumption increments (25 g d–1) are associated with increases in paraoxonase-1 activity (+3.9%, P = 0.030) and declines in cholesteryl ester transfer protein activity (–1.6%, P = 0.021), HDL cholesterol concentrations (–1.1%, P = 0.039), and functions related to HDL levels (cholesterol efflux capacity, –1.1%, P = 0.010). Conclusion Increases in the consumption of virgin olive oil, nuts, legumes, whole grains, and fish (achievable through a regular diet) were associated with improvements in HDL functions in high cardiovascular risk subjects., info:eu-repo/semantics/acceptedVersion
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Quality assessment of controlled clinical trials published in Orthopaedics and Traumatology journals in Spanish, An observational study through handsearching and evidence mapping

  • Arevalo-Rodriguez, Ingrid|||0000-0002-7326-4504
  • Muñoz, Edgar
  • Buitrago-Garcia, Diana|||0000-0001-9761-206X
  • Nuñez-González, Solange
  • Montero-Oleas, Nadia
  • Garzón, Vanessa
  • Pardo-Hernandez, Hector|||0000-0003-3714-0309
  • Bonfill, X. (Xavier)|||0000-0003-1530-3509
Few Orthopaedics and Traumatology journals from Latin America and Spain are indexed in major databases; controlled clinical trials published in these journals cannot be exhaustively retrieved using electronic literature searches. We aimed to identify, describe and assess the quality of controlled clinical trials published in Orthopaedics and Traumatology journals from Latin America and Spain through handsearching and evidence mapping methods. We identified controlled clinical trials published in eligible Orthopaedics/Traumatology journals in Spanish until July 2017 by handsearching. Data were extracted for controlled clinical trials main characteristics and the Cochrane risk of bias tool was used to assess the controlled clinical trials methodological quality. In addition, we mapped the main findings of these trials. As a result, we assessed 5631 references in 29 eligible journals of which 57 were controlled clinical trials (1.0%). Controlled clinical trials were published between 1995 and 2017 at a rate of 2.5 per year. Journals from Spain and Mexico published around 63% of the controlled clinical trials identified. The median sample size of patients enrolled was 60 (range = 30-300 participants). About conditions assessed, 38.5% of controlled clinical trials assessed issues related to knee conditions, 15.7% about hip and 10.5% about trauma or spine. The risk of bias domains most affected was selective reporting bias and random sequence generation. In addition, only two and seven trials had low risk of bias in all items related to participant/personnel and outcome assessment blindings, respectively. More than 40% of studies did not report differences on benefits/harms between the interventions assessed. As a conclusion, the number of controlled clinical trials published in Orthopaedics/Traumatology journals from Latin America and Spain is low. These controlled clinical trials had important methodological shortcomings and were judged as unclear or high risk of bias. These trials are now available in CENTRAL for their potential inclusion in systematic reviews and other documents of synthesis.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Epigenetic-Transcriptional Regulation of Fatty Acid Metabolism and Its Alterations in Leukaemia

  • Maher, Michael|||0000-0002-4956-7185
  • Diesch, Jeannine|||0000-0002-4667-3468
  • Casquero, Raquel
  • Buschbeck, Marcus|||0000-0002-3218-4567
In recent years fatty acid metabolism has gained greater attention in haematologic cancers such as acute myeloid leukaemia. The oxidation of fatty acids provides fuel in the form of ATP and NADH, while fatty acid synthesis provides building blocks for cellular structures. Here, we will discuss how leukaemic cells differ from healthy cells in their increased reliance on fatty acid metabolism. In order to understand how these changes are achieved, we describe the main pathways regulating fatty acid metabolism at the transcriptional level and highlight the limited knowledge about related epigenetic mechanisms. We explore these mechanisms in the context of leukaemia and consider the relevance of the bone marrow microenvironment in disease management. Finally, we discuss efforts to interfere with fatty acid metabolism as a therapeutic strategy along with the use of metabolic parameters as biomarkers.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Modulation of the Gut Microbiota by Olive Oil Phenolic Compounds: Implications for Lipid Metabolism, Immune System, and Obesity

  • Farràs Mañé, Marta|||0000-0001-9776-3773
  • Portune, Kevin
  • Arranz, Sara|||0000-0003-2397-5145
  • Frost, Gary
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Martinez Gili, Laura|||0000-0001-5271-9672
There is extensive information of the beneficial effects of virgin olive oil (VOO), especially on cardiovascular diseases. Some VOO healthy properties have been attributed to their phenolic-compounds (PCs). The aim of this review is to present updated data on the effects of olive oil (OO) PCs on the gut microbiota, lipid metabolism, immune system, and obesity, as well as on the crosstalk among them. We summarize experiments and clinical trials which assessed the specific effects of the olive oil phenolic-compounds (OOPCs) without the synergy with OO-fats. Several studies have demonstrated that OOPC consumption increases Bacteroidetes and/or reduces the Firmicutes/Bacteroidetes ratio, which have both been related to atheroprotection. OOPCs also increase certain beneficial bacteria and gut-bacteria diversity which can be therapeutic for lipid-immune disorders and obesity. Furthermore, some of the mechanisms implicated in the crosstalk between OOPCs and these disorders include antimicrobial-activity, cholesterol microbial metabolism, and metabolites produced by bacteria. Specifically, OOPCs modulate short-chain fatty-acids produced by gut-microbiota, which can affect cholesterol metabolism and the immune system, and may play a role in weight gain through promoting satiety. Since data in humans are scarce, there is a necessity for more clinical trials designed to assess the specific role of the OOPCs in this crosstalk.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Trimethylamine N -Oxide, A Link among Diet, Gut Microbiota, Gene Regulation of Liver and Intestine Cholesterol Homeostasis and HDL Function

  • Canyelles, Marina|||0000-0002-0278-5337
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Cedó, Lídia|||0000-0003-4354-3411
  • Farràs Mañé, Marta|||0000-0001-9776-3773
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
Recent evidence, including massive gene-expression analysis and a wide-variety of other multi-omics approaches, demonstrates an interplay between gut microbiota and the regulation of plasma lipids. Gut microbial metabolism of choline and -carnitine results in the formation of trimethylamine (TMA) and concomitant conversion into trimethylamine- N -oxide (TMAO) by liver flavin monooxygenase 3 (FMO3). The plasma level of TMAO is determined by the genetic variation, diet and composition of gut microbiota. Multiple studies have demonstrated an association between TMAO plasma levels and the risk of atherothrombotic cardiovascular disease (CVD). We aimed to review the molecular pathways by which TMAO production and FMO3 exert their proatherogenic effects. TMAO may promote foam cell formation by upregulating macrophage scavenger receptors, deregulating enterohepatic cholesterol and bile acid metabolism and impairing macrophage reverse cholesterol transport (RCT). Furthermore, FMO3 may promote dyslipidemia by regulating multiple genes involved in hepatic lipogenesis and gluconeogenesis. FMO3 also impairs multiple aspects of cholesterol homeostasis, including transintestinal cholesterol export and macrophage-specific RCT. At least part of these FMO3-mediated effects on lipid metabolism and atherogenesis seem to be independent of the TMA/TMAO formation. Overall, these findings have the potential to open a new era for the therapeutic manipulation of the gut microbiota to improve CVD risk.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Use of the Natural Outdoor Environment in Different Populations in Europe in Relation to Access, Implications for Policy

  • Masterson, Daniel|||0000-0003-4364-9814
  • Triguero-Mas, Margarita|||0000-0002-1580-2693
  • Marquez, Sandra
  • Zijlema, Wilma|||0000-0002-6257-5091
  • Martinez, David|||0000-0001-7001-7674
  • Gidlow, Christopher|||0000-0003-4990-4572
  • Smith, Graham
  • Hurst, Gemma|||0000-0001-6155-1189
  • Cirach, Marta
  • Grazuleviciene, Regina|||0000-0002-0210-8053
  • Van den Berg, Magdalena
  • Kruize, Hanneke|||0000-0003-1366-4677
  • Maas, Jolanda
  • Nieuwenhuijsen, Mark|||0000-0001-9461-7981
This cross-cultural study explores the relationship of natural outdoor environment (NOE) use with NOE access. Most urban planning recommendations suggest optimal accessibility to be 300 m-500 m straight distance to spaces with vegetation of at least 1 hectare. Exploring this recommendation, we used data (n = 3947) from four European cities collected in the framework of the PHENOTYPE study: Barcelona (Spain), Doetinchem (The Netherlands), Kaunas (Lithuania) and Stoke-on-Trent (United Kingdom) to obtain residential access to NOE (straight or network distances, using 300 m and 150 m buffers, to NOE larger than 1 hectare or 0.5 hectare) and use of NOE (i.e., self-reported time spent in NOE). Poisson regression models were used to examine the associations between residential access and use of NOE. The models with the strongest association with time spent in NOE in the combined sample were for those living within 300 m straight line distance to either 0.5 ha or 1 ha NOE. Noting that the only indicator that was consistent across all individual cities was living with 150 m network buffer of NOE (of at least 1 ha), this warrants further exploration in reducing recommendations of 300 m straight-line distance to 150 m network distance to 1 ha of NOE for a general indicator for cities within Europe.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Divergent leukaemia subclones as cellular models for testing vulnerabilities associated with gains in chromosomes 7, 8 or 18

  • Maher, Michael|||0000-0002-4956-7185
  • Diesch, Jeannine|||0000-0002-4667-3468
  • Le Pannérer, Marguerite Marie|||0000-0002-5779-8805
  • Cabezón, Marta|||0000-0001-5122-7481
  • Mallo, Maria del Mar|||0000-0001-7741-498X
  • Vergara, Sara
  • Méndez López, Aleix
  • Mesa Tudel, Alba|||0000-0002-8377-7573
  • Sole, F.|||0000-0002-3251-2161
  • Sorigue, Marc|||0000-0002-0587-591X
  • Zamora, Lurdes|||0000-0003-1713-7110
  • Granada, Isabel|||0000-0002-4275-0104
  • Buschbeck, Marcus|||0000-0002-3218-4567
Haematopoietic malignancies are frequently characterized by karyotypic abnormalities. The development of targeted drugs has been pioneered with compounds against gene products of fusion genes caused by chromosomal translocations. While polysomies are equally frequent as translocations, for many of them we are lacking therapeutic approaches aimed at synthetic lethality. Here, we report two new cell lines, named MBU-7 and MBU-8, that differ in complete trisomy of chromosome18, a partial trisomy of chromosome 7 and a tetrasomy of the p-arm of chromosome 8, but otherwise share the same mutational pattern and complex karyotype. Both cell lines are divergent clones of U-937 cells and have the morphology and immunoprofile of monocytic cells. The distinct karyotypic differences between MBU-7 and MBU-8 are associated with a difference in the specific response to nucleoside analogues. Taken together, we propose the MBU-7 and MBU-8 cell lines described here as suitable in vitro models for screening and testing vulnerabilities that are associated with the disease-relevant polysomies of chromosome 7, 8 and 18.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Impact of Phenol-Enriched Olive Oils on Serum Metabonome and Its Relationship with Cardiometabolic Parameters, A Randomized, Double-Blind, Cross-Over, Controlled Trial

  • Farràs Mañé, Marta|||0000-0001-9776-3773
  • Swann, Jonathan Richard
  • Rowland, Ian
  • Rubió, Laura
  • Subirana, Isaac|||0000-0003-1676-0197
  • Catalán, Úrsula
  • Motilva, Maria-José|||0000-0001-8985-7737
  • Solà, Rosa|||0000-0002-8359-235X
  • Covas Planells, Maria Isabel
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Fitó, Montserrat|||0000-0002-1817-483X
  • Mayneris-Perxachs, Jordi|||0000-0003-3788-3815
Phenol-rich foods consumption such as virgin olive oil (VOO) has been shown to have beneficial effects on cardiovascular diseases. The broader biochemical impact of VOO and phenol-enriched OOs remains, however, unclear. A randomized, double-blind, cross-over, controlled trial was performed with thirty-three hypercholesterolemic individuals who ingested for 3-weeks (25 mL/day): (1) an OO enriched with its own olive oil phenolic compounds (PCs) (500 ppm; FOO); (2) an OO enriched with its own olive oil PCs (250 ppm) plus thyme PCs (250 ppm; FOOT); and (3) a VOO with low phenolic content (80 ppm). Serum lipid and glycemic profiles, serum 1H-NMR spectroscopy-based metabolomics, endothelial function, blood pressure, and cardiovascular risk were measured. We combined OPLS-DA with machine learning modelling to identify metabolites discrimination of the treatment groups. Both phenol-enriched OO interventions decreased the levels of glutamine, creatinine, creatine, dimethylamine, and histidine in comparison to VOO one. In addition, FOOT decreased the plasma levels of glycine and DMSO2 compared to VOO, while FOO decreased the circulating alanine concentrations but increased the plasma levels of acetone and 3-HB compared to VOO. Based on these findings, phenol-enriched OOs were shown to result in a favorable shift in the circulating metabolic phenotype, inducing a reduction in metabolites associated with cardiometabolic diseases.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Virgin Olive Oil Phenolic Compounds Modulate the HDL Lipidome in Hypercholesterolaemic Subjects, A Lipidomic Analysis of the VOHF Study

  • Fernández-Castillejo, Sara|||0000-0002-8109-9713
  • Pedret, Anna
  • Catalán, Úrsula
  • Valls, Rosa Maria|||0000-0002-3351-0942
  • Farràs Mañé, Marta|||0000-0001-9776-3773
  • Rubió, Laura
  • Castañer, Olga|||0000-0003-3169-997X
  • Macià, Alba
  • Fitó, Montserrat|||0000-0002-1817-483X
  • Motilva, Maria José
  • Covas Planells, Maria Isabel
  • Giera, Martin
  • Remaley, Alan T.
  • Solà, Rosa|||0000-0002-8359-235X
Scope: The lipidomic analysis of high-density lipoprotein (HDL) could be useful to identify new biomarkers of HDL function. Methods and results: A randomized, controlled, double-blind, crossover trial (33 hypercholesterolaemic subjects) is performed with a control virgin olive oil (VOO), VOO enriched with its own phenolic compounds (FVOO), or VOO enriched with additional phenolic compounds from thyme (FVOOT) for 3 weeks. HDL lipidomic analyses are performed using the Lipidyzer platform. VOO and FVOO intake increase monounsaturated-fatty acids (FAs) and decrease saturated and polyunsaturated FAs in triacylglyceride (TAG) species, among others species. In contrast, FVOOT intake does not induce these FAs changes. The decrease in TAG52:3(FA16:0) after VOO intake and the decrease in TAG52:5(FA18:2) after FVOO intake are inversely associated with changes in HDL resistance to oxidation. After FVOO intake, the decrease in TAG54:6(FA18:2) in HDL is inversely associated with changes in HDL cholesterol efflux capacity. Conclusion: VOO and FVOO consumption has an impact on the HDL lipidome, in particular TAG species. Although TAGs are minor components of HDL mass, the observed changes in TAG modulated HDL functionality towards a cardioprotective mode. The assessment of the HDL lipidome is a valuable approach to identify and characterize new biomarkers of HDL function.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A functional virgin olive oil enriched with olive oil and thyme phenolic compounds improves the expression of cholesterol efflux-related genes, A randomized, crossover, controlled trial

  • Farràs Mañé, Marta|||0000-0001-9776-3773
  • Arranz, Sara|||0000-0003-2397-5145
  • Carrión, Silvia|||0000-0002-1354-2488
  • Subirana, Isaac|||0000-0003-1676-0197
  • Muñoz Aguayo, Daniel|||0000-0001-8173-0168
  • Blanchart, Gemma|||0000-0003-1965-8235
  • Kool, Marjon
  • Solà, Rosa|||0000-0002-8359-235X
  • Motilva, María José
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Rubió, Laura
  • Fernández-Castillejo, Sara|||0000-0002-8109-9713
  • Pedret, Anna
  • Estruch, Ramón|||0000-0003-1260-4445
  • Covas Planells, Maria Isabel
  • Fitó, Montserrat|||0000-0002-1817-483X
  • Hernáez, Álvaro|||0000-0001-8593-1477
  • Castañer, Olga|||0000-0003-3169-997X
The consumption of antioxidant-rich foods such as virgin olive oil (VOO) promotes high-density lipoprotein (HDL) anti-atherogenic capacities. Intake of functional VOOs (enriched with olive/thyme phenolic compounds (PCs)) also improves HDL functions, but the gene expression changes behind these benefits are not fully understood. Our aim was to determine whether these functional VOOs could enhance the expression of cholesterol efflux-related genes. In a randomized, double-blind, crossover, controlled trial, 22 hypercholesterolemic subjects ingested for three weeks 25 mL/day of: (1) a functional VOO enriched with olive oil PCs (500 mg/kg); (2) a functional VOO enriched with olive oil (250 mg/kg) and thyme PCs (250 mg/kg; FVOOT), and; (3) a natural VOO (olive oil PCs: 80 mg/kg, control intervention). We assessed whether these interventions improved the expression of cholesterol efflux-related genes in peripheral blood mononuclear cells by quantitative reverse-transcription polymerase chain reactions. The FVOOT intervention upregulated the expression of CYP27A1 (P = 0.041 and P = 0.053, versus baseline and the control intervention, respectively), CAV1 (P = 0.070, versus the control intervention), and LXRβ, RXRα, and PPARβ/δ (P = 0.005, P = 0.005, and P = 0.038, respectively, relative to the baseline). The consumption of a functional VOO enriched with olive oil and thyme PCs enhanced the expression of key cholesterol efflux regulators, such as CYP27A1 and nuclear receptor-related genes.
e_Buah Biblioteca Digital Universidad de Alcalá
Publication Artículo científico (JournalArticle)

2D diffusion-ordered 1 H-NMR spectroscopy lipidomic profiling after oral single macronutrient loads: influence of obesity, sex, and female androgen excess

  • Insenser Nieto, María Rosa
  • Moncayo Martín, Samuel
  • Martínez García, María Ángeles
  • Fernández Durán, Elena
  • Samino Gené, Sara
  • Álvarez Blasco, Francisco
  • Luque Ramírez, Manuel
  • Escobar Morreale, Héctor Francisco|||0000-0002-6890-1644
9 p., Scope: Postprandial dysmetabolism plays a major role in the pathogenesis of metabolic disorders such as obesity and the polycystic ovary syndrome (PCOS). The aim is to characterize the circulating lipoprotein particle profiles in response to oral glucose, lipid, and protein challenges. Methods and results: 17 women with PCOS, 17 control women, and 19 healthy men selected to have similar age and body mass index are studied. Blood samples are collected following the ingestion of 300 kcal in the form of glucose, lipids, or proteins, and they are submitted to two-dimensional (2D) diffusion-ordered 1 H-NMR spectroscopy. Regardless of macronutrient administered, the number of very low-density (VLDL) particles increases whereas low density-lipoprotein (LDL) decreases. High density-lipoprotein (HDL) particles increase only after lipid ingestion. Obese subjects show an increase in the number of large VLDL particles and a decrease in large LDL particles, with a significant reduction in the average particle size of LDL. Patients with PCOS show a particularly unfavorably smaller LDL particle size response to oral lipid intake, regardless of obesity. Conclusions: Oral macronutrient challenges induce immediate class-specific postprandial changes in particle number and size of lipoproteins, with lipids inducing a more pro-atherogenic lipoprotein profile compared to glucose and proteins, particularly in obese subjects and women with PCOS., Instituto de Salud Carlos III, Fondo Europeo de Desarrollo Regional (FEDER), Ministerio de Ciencia, Innovación y Universidades, Ministerio de Economía y Competitividad
e_Buah Biblioteca Digital Universidad de Alcalá
Publication Artículo científico (JournalArticle)

Acute-phase glycoprotein profile responses to different oral macronutrient challenges: Influence of sex, functional hyperandrogenism and obesity

  • Moncayo Martín, Samuel
  • Insenser Nieto, María Rosa
  • Martínez García, María Ángeles
  • Fuertes Martín, Rocío
  • Amigó Grau, Núria
  • Álvarez Blasco, Francisco
  • Luque Ramírez, Manuel
  • Correig Blanchar, Francesc Xavier
  • Escobar Morreale, Héctor Francisco|||0000-0002-6890-1644
6 p., Acute-phase glycoprotein 1H-NMR spectroscopy profiles serve as surrogate markers of chronic inflammation in metabolic disorders such as obesity, diabetes and polycystic ovary syndrome (PCOS). The latter is associated with increased height-to-width (H/W) ratios of GlycA and GlycB after fasting, but not to glycoprotein areas, regardless of obesity. We studied the responses to separate glucose, lipid and protein oral challenges of five glycoprotein variables (GlycA, GlycB, and GlycF areas and the GlycA and GlycB H/W ratios) in 17 women with PCOS, 17 control women, and 19 healthy men. Glucose and protein ingestion resulted into decreases in all glycoprotein variables, whereas lipid ingestion increased GlycA, GlycF and induced minimal changes in GlycB and GlycB H/W. We found no effects of obesity or group of subjects on postprandial glycoprotein variables regardless of the macronutrient being ingested. However, a statistically significant interaction indicated that obesity blunted the decrease in some of these variables in control women and men, whereas obese women with PCOS showed larger changes when compared with their non-obese counterparts. In conclusion, acute-phase glycoprotein profiles indicate an anti-inflammatory response during postprandial phase that is less pronounced after lipid ingestion, and is counteracted by the chronic inflammatory background associated with obesity and PCOS., Instituto de Salud Carlos III, Fondo Europeo de Desarrollo Regional (FEDER) "Una manera de hacer Europa", Ministerio de Ciencia, Innovación y Universidades, Ministerio de Economía y Competitividad, Universidad Rovira i Virgili, Generalitat de Catalunya